OLMA250117C15000
- 0.15
- 0.000.00%
Olema Pharmaceuticals Newsroom
Insider Purchase: 10% Owner at $OLMA (OLMA) Buys 300,000 Shares
Bain Capital Life Sciences Buys $1.7m in Olema Pharmaceuticals Stock
Olema Pharmaceuticals Advances in Cancer Therapy Development
Top Midday Decliners
Express News | Olema Pharmaceuticals Inc Files for Mixed Shelf of up to $200 Mln - SEC Filing
Express News | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
(SEC Amendment) Olema Pharmaceuticals(OLMA.US) Director Buys US$4.73 Million in Common Stock
Top 3 Health Care Stocks That May Explode In Q4
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $30
J.P. Morgan Keeps Their Buy Rating on Olema Pharmaceuticals (OLMA)
Olema Pharmaceuticals Director Graham Walmsley Sells $4.73m in Stock
Express News | Olema Pharmaceuticals Inc : JP Morgan Raises Target Price to $30 From $29
Express News | Form 144 | Olema Pharmaceuticals(OLMA.US) Insider Proposes to Sell 4.73 Million in Common Stocks
Olema Pharmaceuticals Down Over 19%, on Pace for Largest Percent Decrease Since August 2022 -- Data Talk
Insider Sale: Director at $OLMA (OLMA) Sells 8,256 Shares
Express News | Bain Capital Life Sciences Opportunities IV, L.p. Reports 9.99% Passive Stake in Olema Pharmaceuticals Inc as of Dec 4 - SEC Filing
Oppenheimer Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $30
Oppenheimer Remains a Buy on Olema Pharmaceuticals (OLMA)